Non-alcoholic Fatty Liver Disease (NAFLD)
76
10
19
33
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
17 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
3.9%
3 terminated out of 76 trials
91.7%
+5.2% vs benchmark
7%
5 trials in Phase 3/4
52%
17 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (76)
Evaluating the Pharmacokinetics and Safety of Miricorilant
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Milk Thistle Clinical Trial in Pediatric NAFLD
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
Interest of APA in Fatty Liver Disease Evaluation of Efficacy and Adherence to an Adapted Physical Activity (APA) Program in Patients With Metabolic Fatty Liver Disease
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk
Exploratory Study of MRI Biomarkers of NASH
Study to Evaluate the Effectiveness of Legalon®
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease